H.C. Wainwright raised the firm’s price target on Ultragenyx (RARE) to $95 from $82 and keeps a Buy rating on the shares post the Q3 report. The firm believes the company’s path to profitability in 2026 is achievable.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE: